Observational Study With Everolimus (Certican) in Combination With Low-dose Cyclosporine in De Novo Heart Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 26, Issue 7, 2007, Pages 700-704

  Lehmkuhl, Hans B ^a   Mai, Daniel ^a   Dandel, Michael ^a   Knosalla, Christoph ^a   Hiemann, Nicola E ^a   Grauhan, Onnen ^a   Huebler, Michael ^a   Pasic, Miralem ^a   Weng, Yuguo ^a   Meyer, Rudolph ^a   Rothenburger, Markus ^b   Hummel, Manfred ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CARBON MONOXIDE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

ADULT; CHOLESTEROL; CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TREATMENT OUTCOME;

EID: 34347233810     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.02.008     Document Type: Article

References (22)

1. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
2. Valantine H., and Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 24 suppl (2005) S185-S190
3. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525
4. Keck B.M., Bennett L.E., Rosendale J., Dailey O.P., Novick R.J., and Hosenpud J.D. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transplant 13 (1999) 35-49
5. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Curr Control Trials Cardiovasc Med 1 (2000) 166-171
6. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomised clinical trial. Circulation 110 (2004) 2694-2700
7. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation 108 (2003) 48-53
8. Viklicky O., Zou H., Muller V., et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 69 (2000) 497-503
9. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532-1540
10. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
11. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimised cyclosporine dosing in renal transplant recipient: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
12. Nashan B., Curtis J., Ponticelli C., et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomised, multicenter, open-label study. Transplantation 78 (2004) 1332-1340
13. Kovarik J.M., Eisen H., Dorent R., et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 22 (2003) 1117-1125
14. Lehmkuhl H., and Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutches Herzzentrum Berlin. J Heart Lung Transplant 24 suppl (2005) S201-S205
15. Starling R.C., Hare J.M., Hauptman P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 4 (2004) 2126-2131
16. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transplant 24 suppl (2005) S196-S200
17. Dandel M., Hummel M., Muller J., et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 104 suppl I (2001) I-184-I-191
18. Müller J., Eubel A., Dandel M., Hummel M., and Hetzer R. Non-invasive monitoring of rejection after cardiac transplantation. The method and retrospective analysis of data on 734 patients. Dtsch Med Wochenschr 126 (2001) 1223-1228
19. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
20. Pamboukian S.V., Costanzo M.R., Dunlap S., et al. Relationship between bridging with ventricular assist device on rejection after heart transplantation. J Heart Lung Transplant 24 (2005) 310-315
21. Gonzalez-Stawinski G.V., Cook D.J., Chang A.S.Y., et al. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. J Heart Lung Transplant 25 (2006) 613-618
22. Lehmkuhl H., Ross H., Eisen H., and Valantine H. Everolimus (Certican) in heart transplantation-optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 37 (2005) 4145-4149